Vaccines, Virus-Like Particle
"Vaccines, Virus-Like Particle" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Vaccines using supra-molecular structures composed of multiple copies of recombinantly expressed viral structural proteins. They are often antigentically indistinguishable from the virus from which they were derived.
MeSH Number(s)
D12.776.828.868.955
D20.215.894.865.955
D23.050.865.955
Concept/Terms
Vaccines, Virus-Like Particle- Vaccines, Virus-Like Particle
- Particle Vaccines, Virus-Like
- Vaccines, Virus Like Particle
- Virus-Like Particle Vaccines
- Virus Like Particle Vaccines
Below are MeSH descriptors whose meaning is more general than "Vaccines, Virus-Like Particle".
Below are MeSH descriptors whose meaning is more specific than "Vaccines, Virus-Like Particle".
This graph shows the total number of publications written about "Vaccines, Virus-Like Particle" by people in Harvard Catalyst Profiles by year, and whether "Vaccines, Virus-Like Particle" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 0 | 2 | 2 |
| 2013 | 1 | 1 | 2 |
| 2014 | 3 | 1 | 4 |
| 2015 | 4 | 1 | 5 |
| 2016 | 3 | 2 | 5 |
| 2017 | 2 | 1 | 3 |
| 2018 | 1 | 0 | 1 |
| 2019 | 2 | 0 | 2 |
| 2020 | 2 | 1 | 3 |
| 2021 | 1 | 3 | 4 |
| 2022 | 3 | 0 | 3 |
Below are the most recent publications written about "Vaccines, Virus-Like Particle" by people in Profiles.
-
A bacterially expressed triple-type chimeric vaccine against human papillomavirus types 51, 69, and 26. Vaccine. 2022 10 06; 40(42):6141-6152.
-
Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial. Lancet Infect Dis. 2022 Dec; 22(12):1756-1768.
-
RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge. mSphere. 2022 08 31; 7(4):e0024322.
-
Engineering an Antibody V Gene-Selective Vaccine. Front Immunol. 2021; 12:730471.
-
Expression of SARS coronavirus 1 spike protein from a herpesviral vector induces innate immune signaling and neutralizing antibody responses. Virology. 2021 07; 559:165-172.
-
COVID-19 vaccine decisions: considering the choices and opportunities. Microbes Infect. 2021 May-Jun; 23(4-5):104811.
-
SARS-CoV-2 vaccines for cancer patients: a call to action. Eur J Cancer. 2021 05; 148:316-327.
-
A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice. Cell Res. 2020 10; 30(10):936-939.
-
Rational design of a multi-valent human papillomavirus vaccine by capsomere-hybrid co-assembly of virus-like particles. Nat Commun. 2020 06 05; 11(1):2841.
-
Prophylactic Hepatitis E Vaccines: Antigenic Analysis and Serological Evaluation. Viruses. 2020 01 16; 12(1).